Citi Raises Price Target on Merck (MRK), Citing Strong Pipeline and Oncology Strength

Core Insights - Merck & Co., Inc. (NYSE:MRK) is recognized for its strong oncology portfolio, particularly its flagship drug Keytruda, which is the top-selling medicine globally [2] - The company has been actively expanding through acquisitions, including the $3.4 billion purchase of SpringWorks Therapeutics in 2025 [3] - Analysts maintain a positive outlook on Merck, with Citi raising its price target from $84 to $95, emphasizing the importance of Keytruda Qlex, Winrevair, and the broader drug pipeline [4] Financial Performance - Merck has demonstrated consistent dividend growth, increasing its payouts for 16 consecutive years, with a current quarterly dividend of $0.81 per share and a dividend yield of 3.81% as of October 14 [5]